Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hashim Hashim & Paul Abrams. (2010) Emerging drugs for the treatment of benign prostatic obstruction. Expert Opinion on Emerging Drugs 15:2, pages 159-174.
Read now
Read now
J Paul Hieble & Robert R Ruffolo. (1997) Recent advances in the identification of a 1- and a 2-adrenoceptor subtypes: therapeutic implications. Expert Opinion on Investigational Drugs 6:4, pages 367-387.
Read now
Read now
Articles from other publishers (20)
Claudius Füllhase & Marc P. Schneider. (2016) 5-Alpha-Reductase Inhibitors and Combination Therapy. Urologic Clinics of North America 43:3, pages 325-336.
Crossref
Crossref
Hisao Nagaya, Yusuke U. Nakagawa & Akinobu Gotoh. (2015) Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs. Personalized Medicine Universe 4, pages 23-26.
Crossref
Crossref
Jacek Lewandowski, Maciej Sinski, Bartosz Symonides, Jerzy Korecki, Krzysztof Rogowski, Jacek Judycki, Artur Sieczych, Olga Możeńska & Zbigniew Gaciong. (2013) Beneficial Influence of Carvedilol on Urologic Indices in Patients With Hypertension and Benign Prostatic Hyperplasia: Results of a Randomized, Crossover Study. Urology 82:3, pages 660-666.
Crossref
Crossref
Claudius Füllhase, Christopher Chapple, Jean-Nicolas Cornu, Cosimo De Nunzio, Christian Gratzke, Steven A. Kaplan, Michael Marberger, Francesco Montorsi, Giacomo Novara, Matthias Oelke, Hartmut Porst, Claus Roehrborn, Christian Stief & Kevin T. McVary. (2013) Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms. European Urology 64:2, pages 228-243.
Crossref
Crossref
Timothy J Wilt, Roderick MacDonald & Indy Rutks. (2011) Tamsulosin for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yukio Homma, Isao Araki, Yasuhiko Igawa, Seiichiro Ozono, Momokazu Gotoh, Tomonori Yamanishi, Osamu Yokoyama & Masaki Yoshida. (2009) Clinical guideline for male lower urinary tract symptoms. International Journal of Urology 16:10, pages 775-790.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Nobuyuki Goya, Kotaro Gotanda, Takako Sasaki, Mami Okada, Yasuko Tomizawa & Hiroshi Toma. (2006) Local injection of a sustained‐release antiandrogen formulation into a target prostatic site: an experimental study. BJU International 99:1, pages 202-206.
Crossref
Crossref
R. BARBERO, P. BADINO, R. ODORE, M. R. GALMOZZI, B. CUNIBERTI, R. ZANATTA & G. RE. (2006) Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats. Journal of Veterinary Pharmacology and Therapeutics 29:4, pages 289-297.
Crossref
Crossref
Jin Seon ChoKyung Seop LeeBup Wan KimSae Woong KimChoung Soo KimChoong Hee NohHyun Yul RhewKwangsung Park, Dong Soo ParkJae Shin ParkJong Kwan ParkIll Young SeoTae Hee OhSang Eun LeeByung Ha ChungSe Il JungJae Il ChungHee Chang JungIn Rae ChoChun Il Kim. (2006) The Influence of Chlormadinone Acetate on the Total and Free Serum Prostate Specific Antigen Levels in Men with Benign Prostatic Hyperplasia. Korean Journal of Urology 47:4, pages 368.
Crossref
Crossref
Osamu Ishizuka, Osamu Nishizawa, Yoshihiko Hirao & Shinichi Ohshima. (2002) Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. International Journal of Urology 9:11, pages 607-612.
Crossref
Crossref
Timothy Wilt, Roderick MacDonald & Indy Rutks. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Katherine A. Lyseng-Williamson, Blair Jarvis & Antona J. Wagstaff. (2002) Tamsulosin. Drugs 62:1, pages 135-167.
Crossref
Crossref
TIMOTHY J. WILT, RODERICK MacDONALD & DAVID NELSON. (2002) TAMSULOSIN FOR TREATING LOWER URINARY TRACT SYMPTOMS COMPATIBLE WITH BENIGN PROSTATIC OBSTRUCTION:. The Journal of Urology, pages 177-183.
Crossref
Crossref
TIMOTHY J. WILT, RODERICK MacDONALD & DAVID NELSON. (2002) TAMSULOSIN FOR TREATING LOWER URINARY TRACT SYMPTOMS COMPATIBLE WITH BENIGN PROSTATIC OBSTRUCTION: A SYSTEMATIC REVIEW OF EFFICACY AND ADVERSE EFFECTS. Journal of Urology 167:1, pages 177-183.
Crossref
Crossref
G. Re, P. Badino, R. Odore, D. Vigo, A. Bonabello, S. Rabino, F. Capello & T. Bruzzese. (2001) Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats. Pharmacological Research 44:2, pages 141-147.
Crossref
Crossref
Yukio Homma, Kozo Hamada, Yasuhisa Nakayama, Gozoh Tsujimoto & Kazuki Kawabe. (2009)
Effects of castration on contraction and α
1
‐adrenoceptor expression in rat prostate
. British Journal of Pharmacology 131:7, pages 1454-1460.
Crossref
Crossref
H. Okada, S. Kamidono, T. Yoshioka, A. Okuyama, S. Ozono, Y. Hirao, E. Okajima, K. Yamamoto, T. Kishimoto, Y. Park & T. Kurita. (2001) A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU International 85:6, pages 676-681.
Crossref
Crossref
Ashutosh Tewari & Perinchery Narayan. (1999) Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology 53:3, pages 14-20.
Crossref
Crossref
PERINCHERY NARAYAN & ASHUTOSH TEWARI. (1998) A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology 160:5, pages 1701-1706.
Crossref
Crossref